Mirati Therapeutics (NASDAQ:MRTX) Upgraded at Scotiabank : c

Scotiabank upgraded shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) from an underperform rating to a sector perform rating in a research report sent to investors on Monday morning, MarketBeat reports. The firm currently has $58.00 target price on the biotechnology company’s stock. Other research analysts also recently issued research reports about the company. JMP […]

Related Keywords

United States , Stifel Nicolaus , Jamie Christensen , Faheem Hasnain , Goldman Sachs Group Inc , Jefferies Financial Group , Blackrock Inc , Securities Exchange Commission , Armistice Capital , Morgan Stanley , Mirati Therapeutics Inc , Scotiabank , Mirati Therapeutics , Free Report , Financial Group , Get Free Report , Exchange Commission , Director Faheem Hasnain , Sachs Group , Mirati Therapeutics Daily , Nasdaq Mrtx , Mrtx , Medical , Upgrade ,